New prophylactic treatment

New prophylactic treatment

Colin Kerr

Published: Thursday, April 1, 2021

Santen has announced the launch of Ducressa, a fixed-dose combination (FDC) of levofloxacin/ dexamethasone eye drops solution that is indicated for the prevention and treatment of inflammation, and the prevention of infection associated with cataract surgery in adults. “With the launch of this new FDC, many ophthalmologists now have a new approach in their practice to prevent infection in their cataract surgery patient,” said Prof Marc Coassin, University of Rome, Italy. www.santen.eu

Latest Articles

ESCRS Today 2025: Happy Anniversaries!

ESCRS celebrates milestones with pioneers in IOLs, LASIK, femtosecond lasers, and corneal transplantation.

ESCRS Today 2025: A Congress for Everyone

From YOs to families, the ESCRS Annual Meeting embraces full participation through inclusivity.

ESCRS Today 2025: All Eyes on Innovation

Watching out for obstacles and opportunities

Beyond the Numbers

Empowering patient participation fosters continuous innovation in cataract surgery.

Thinking Beyond the Surgery Room

Practice management workshop focuses on financial operations and AI business applications.

Aid Cuts Threaten Global Eye Care Progress

USAID closure leads retreat in development assistance.

Supplement: ESCRS Clinical Trends Series: Presbyopia

Debate: FS-LASIK or KLEx for Hyperopia?

FS-LASIK has more of a track record, but KLEx offers advantages.

Four AI Applications Ready for Practice

Commercial offerings may save time, improve practice and research.

Perioperative Medication Regimens for Cataract Surgery

Randomised controlled clinical trial results provide evidence-based guidance.